<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357849</url>
  </required_header>
  <id_info>
    <org_study_id>11-199</org_study_id>
    <nct_id>NCT02357849</nct_id>
  </id_info>
  <brief_title>Fluoxetine vs Aripiprazole Comparative Trial (FACT)</brief_title>
  <acronym>FACT</acronym>
  <official_title>The Role of Antidepressants or Antipsychotics in Preventing Psychosis: Fluoxetine vs Aripiprazole Comparative Trial (FACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are conducting a randomized, 24-week, double-blind study, comparing fluoxetine with
      aripiprazole in 48 patients with attenuated positive symptoms at a level of at least moderate
      severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To Compare Fluoxetine and Aripiprazole on All-cause Discontinuation/Need to Add Another
      Psychiatric Medication, Symptomatic Improvement, and Adverse Effects
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Time to either all-cause-discontinuation or need to add another psychotropic agent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Prodromal Symptoms (SOPS) total scores</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with specific adverse effects</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in social and role functioning scores</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective well-being questionnaire</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Attenuated Psychosis Syndrome</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (2mg wk1, 5mg wk2, 10mg wk3, 5-30 mg wk4-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need (5-30mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (5mg wk1, 10mg wk2, 20mg wk3, 10-60mg wk3-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need(10-60mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Fluoxetine</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  consent obtained from patients and their parents (assent for patients under 18);

          -  age 12-25 years (inclusive);

          -  English-speaking;

          -  at least one positive (Scale A) SOPS score of 3-5, i.e., moderate, moderately severe
             or severe.

        Exclusion Criteria:

          -  lifetime diagnosis of an Axis I psychotic disorder, including: schizophreniform
             disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or major
             depression with psychotic features;

          -  current psychosis (any positive symptom SOPS score of 6, i.e., extreme);

          -  current diagnosis of Major Depressive Disorder, single episode or recurrent, severe
             without psychotic features;

          -  current stimulant treatment;

          -  history of neurological, neuroendocrine or other medical condition known to affect the
             brain;

          -  any significant medical condition that contra-indicates treatment with either
             aripiprazole or fluoxetine;

          -  past or current substance dependence; sunstance abuse within the last 4 weeks;

          -  IQ &lt; 70.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph U Correll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Shore LIJ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph U Correll, MD</last_name>
    <phone>718-470-4812</phone>
    <email>ccorrell@nshs.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Birnbaum, MD</last_name>
    <phone>718-470-8305</phone>
    <email>Mbirnbaum@nshs.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph U Correll, MD</last_name>
      <phone>718-470-4812</phone>
      <email>ccorrell@nshs.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Christoph U. Correll, MD</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Molecular Medicine Hofstra North Shore LIJ School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

